✨ Onyx Summary Geron Corporation announced it will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference in Boston on September 4, 2025, with a live webcast accessible on its investor website. The appearance highlights Geron’s investor engagement strategy as it advances commercialization of RYTELO® and progresses
✨ Onyx Summary Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in three upcoming investor events - Citi’s 2025 Biopharma Back to School Summit, the Wells Fargo Healthcare Conference, and the Morgan Stanley Global Healthcare Conference - where management will engage in one-on-one meetings with investors. The company continues to advance
✨ Onyx Summary Legend Biotech announced that CEO Ying Huang, Ph.D., will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 9, 2025. The event will be webcast live via the company’s investor relations site as Legend continues to expand its CAR-T leadership and
✨ Onyx Summary Perspective Therapeutics announced participation in multiple investor conferences in September 2025, including fireside chats and panel discussions at the Cantor Global Healthcare, Morgan Stanley Global Healthcare, and OPCO Targeted Radiopharmaceutical Therapies Summits in New York. The company’s leadership will engage with investors and industry peers to discuss
✨ Onyx Summary MassBio’s 2025 Industry Snapshot revealed the first biopharma job losses in Massachusetts R&D and manufacturing in years, driven by a sharp drop in venture funding, sluggish IPOs, and federal policy uncertainty. Yet with unmatched scientific talent, a dense innovation ecosystem, and renewed state support, the
✨ Onyx Summary Seer, Inc. (Nasdaq: SEER) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, featuring a fireside chat at 12:20 p.m. ET. A live webcast and replay will be accessible on the company’s investor website. On August 26, 2025, Seer
✨ Onyx Summary ImmunityBio announced early pilot data in recurrent glioblastoma showing that all five patients treated with its combination of ANKTIVA® (an IL-15 agonist), NK cell therapy, and Optune Tumor Treating Fields achieved disease control, including two near-complete responses. Glioblastoma is among the most aggressive brain cancers, with limited treatment
✨ Onyx Summary Guardant Health will present in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025—an appearance that underscores its prominence as a leader driving the future of precision oncology and cancer screening innovation. PALO ALTO, Calif.– Guardant Health, Inc. (Nasdaq: GH)
✨ Onyx Summary Piramal Pharma Limited released its FY2025 Sustainability Report, detailing measurable progress across governance, climate action, diversity, and community impact under its four sustainability pillars. The report highlights a 6% cut in Scope 1 and 2 emissions, expanded renewable energy use to 20%, and strengthened DE&I representation,
✨ Onyx Summary Phathom Pharmaceuticals announced that its management team will present at the Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8, 2025, with live webcasts and replays available on the company’s website. Management will also participate in one-on-one investor
✨ Onyx Summary Kyverna Therapeutics announced that CEO Warner Biddle will participate in fireside chats at the 2025 Wells Fargo, Morgan Stanley, and H.C. Wainwright Global Healthcare Conferences in early September. The presentations will be webcast live via Kyverna’s investor relations website, with replays available for 90 days. EMERYVILLE,
✨ Onyx Summary Phathom Pharmaceuticals clarified that an upcoming Schedule 13D filing by Frazier Life Sciences reflects only administrative reporting changes and does not reduce Frazier’s ownership in the company. By affirming that no shares have been sold, Phathom underscores continued investor commitment at a pivotal time in advancing its
✨ Onyx Summary Keros Therapeutics received U.S. FDA Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy, recognizing its potential to address a rare and serious condition with limited therapies. The designation provides regulatory and financial incentives as Keros advances KER-065 toward a planned Phase 2 trial
✨ Onyx Summary Rocket Pharmaceuticals announced that the FDA has lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disease, allowing the study to resume at a recalibrated lower dose with updated safety protocols. The swift resolution marks a key milestone for one of the most
✨ Onyx Summary Nucleus RadioPharma appointed former FDA Commissioner Dr. Stephen M. Hahn as chief executive officer to lead its expansion in radiopharmaceutical manufacturing and infrastructure. Backed by $72 million in funding and partnerships with Eclipse, Mayo Clinic, and AstraZeneca, Hahn will focus on scaling GMP readiness, expanding R&D,
✨ Onyx Summary SpyGlass Pharma appointed Elizabeth (Liz) O’Farrell, former Eli Lilly executive, to its Board of Directors as Independent Director and Chair of the Audit Committee. O’Farrell’s extensive background in finance, governance, and global operations strengthens SpyGlass’s leadership as it advances its long-acting ophthalmic drug delivery
